This federal Project Grant award from the National Cancer Institute's Cancer Detection and Diagnosis Research program (CFDA 93.394) provides $231,413 to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), to develop a technology called SPINEX for rapid, high-throughput isolation and characterization of extracellular vesicles (EVs) from blood plasma.
The goal is to overcome technical hurdles in translating EV-based biomarkers into reliable cancer diagnostic tests. The SPINEX platform integrates dual-mode chromatography and disc-based fluidics to selectively enrich EVs while removing interfering lipoprotein particles. This project will build a prototype SPINEX system and evaluate its performance in processing clinical ovarian cancer samples. The results could enable large-scale clinical studies on EV-based cancer biomarkers and democratize EV testing for improved early cancer detection. The award period is from January 1, 2025 to December 31, 2027.
Generated 1/28/25, 11:09 AM